Cited by

• Autoantibody response to a novel tumor-associated antigen p90/CIP2A in breast cancer immunodiagnosis.

  Liu X, Chai Y, Li J, Ren P, Liu M, Dai L, Qian W, Li W, Zhang JY. Liu X, et al. Tumour Biol. 2014 Mar;35(3):2661-7. doi: 10.1007/s13277-013-1350-6. Epub 2014 Jan 8. Tumour Biol. 2014. PMID: 24399648 Free PMC article.
• Expression of CIP2A in renal cell carcinomas correlates with tumour invasion, metastasis and patients' survival.

  Ren J, Li W, Yan L, Jiao W, Tian S, Li D, Tang Y, Gu G, Liu H, Xu Z. Ren J, et al. Br J Cancer. 2011 Dec 6;105(12):1905-11. doi: 10.1038/bjc.2011.492. Epub 2011 Nov 10. Br J Cancer. 2011. PMID: 22075943 Free PMC article.
• CIP2A is overexpressed and involved in the pathogenesis of chronic myelocytic leukemia by interacting with breakpoint cluster region-Abelson leukemia virus.

  Wang J, Huang T, Sun J, Yu Y, Liu Z, Li W, Jia J, Chen C. Wang J, et al. Med Oncol. 2014 Aug;31(8):112. doi: 10.1007/s12032-014-0112-7. Epub 2014 Jul 15. Med Oncol. 2014. PMID: 25023053
• CIP2A with survivin protein expressions in human non-small-cell lung cancer correlates with prognosis.

  Xu P, Xu XL, Huang Q, Zhang ZH, Zhang YB. Xu P, et al. Med Oncol. 2012 Sep;29(3):1643-7. doi: 10.1007/s12032-011-0053-3. Epub 2011 Aug 28. Med Oncol. 2012. PMID: 21874565
• Validation of CIP2A as a Biomarker of Subsequent Disease Progression and Treatment Failure in Chronic Myeloid Leukaemia.

  Clark RE, Basabrain AA, Austin GM, Holcroft AK, Loaiza S, Apperley JF, Law C, Scott L, Parry AD, Bonnett L, Lucas CM. Clark RE, et al. Cancers (Basel). 2021 Apr 29;13(9):2155. doi: 10.3390/cancers13092155. Cancers (Basel). 2021. PMID: 33947031 Free PMC article.